Novel Peroxisome Proliferator-Activated Receptor α Agonists Lower Low-Density Lipoprotein and Triglycerides, Raise High-Density Lipoprotein, and Synergistically Increase Cholesterol Excretion with a Liver X Receptor Agonist

Ranjan Mukherjee(Ligand Pharmaceuticals (United States)), Rai Ajit K. Srivastava(Drexel University), Peter T. W. Cheng(Bristol-Myers Squibb (United States)), Michael A. Blanar(Bristol-Myers Squibb (United States)), Rongan Zhang(Bristol-Myers Squibb (United States)), Michael A. Flynn, Bowman Miao(Louisville Metabolic and Atherosclerosis Research Center), Lawrence J. Kennedy(Bristol-Myers Squibb (United States)), Debra Search(Louisville Metabolic and Atherosclerosis Research Center), Hossain Monshizadegan(Louisville Metabolic and Atherosclerosis Research Center), Kenneth T. Locke(Medicines Evaluation Unit), Joseph A. Tino(Institut des Maladies Métaboliques et Cardiovasculaires), Jun Li(Bristol-Myers Squibb (United States)), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Kevin O’Malley(Medicines Evaluation Unit), Denise Grimm(Louisville Metabolic and Atherosclerosis Research Center), Daniel S. Meyers(Louisville Metabolic and Atherosclerosis Research Center), Yan Shi(Institut des Maladies Métaboliques et Cardiovasculaires)
Journal of Pharmacology and Experimental Therapeutics
September 18, 2008
Cited by 35


Related Papers